Placebo-subtracted mean weight loss up to 14.1%after 28 weeks with no plateauPotential for best-in-class tolerability with minimal diarrhea ...

MindRank AI Ltd., a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced the positive topline results of its oral small-molecule GLP-1 receptor agonist MDR-001 ...

Pfizer enters the obesity drug market with its Metsera acquisition, aiming to challenge leaders Eli Lilly and Novo Nordisk. Read more here.

Ladies and gentlemen, greetings, and welcome to MBX Biosciences Conference Call. Today's call is being recorded. [Operator Instructions] As a reminder, this conference is being recorded. It is now my ...

Long-Term Efficacy and Tolerability of Aficamten in Patients with Non-Obstructive HCM Pre-Specified Analysis of Supplemental Endpoints from MAPLE-HCM Shows Aficamten Improves Measures of Submaximal ...

Quality control is an essential manufacturing expense, yet its true financial impact often goes unnoticed. Hidden costs tied to quality assurance can represent ...

In the SIBAMATE study, more than 60% of patients lost at least 5% of body weight after 3 months of using sibutramine-topiramate.

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Anti-inflammatory reliever ...

VIENNA — Tirzepatide was associated with improvements in body weight and body composition, and with lower insulin doses, in the first-ever randomized controlled trial (RCT) of the drug in people with ...

Cytokinetics (CYTK) announced that additional data related to aficamten were presented in a Late Breaking Clinical Research session at the Heart ...